Cargando…

Toxicological Evaluation and In Silico Identification of Acetylcholinesterase Inhibitors in a Commercial Polyherbal Formulation (KWAPF01)

This study investigated the toxicological implications of a commercial polyherbal formulation, KWAPF01. Twenty-four Wistar rats were randomized into six groups of four animals per group. The animals in Group 1 were administered placebo and designated as control, while the rats in Groups 2 to 6 were...

Descripción completa

Detalles Bibliográficos
Autores principales: Aladodo, A. Raliat, Ibrahim, Ibrahim O., Sabiu, Saheed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307333/
https://www.ncbi.nlm.nih.gov/pubmed/35873645
http://dx.doi.org/10.1155/2022/4388941
_version_ 1784752733629186048
author Aladodo, A. Raliat
Ibrahim, Ibrahim O.
Sabiu, Saheed
author_facet Aladodo, A. Raliat
Ibrahim, Ibrahim O.
Sabiu, Saheed
author_sort Aladodo, A. Raliat
collection PubMed
description This study investigated the toxicological implications of a commercial polyherbal formulation, KWAPF01. Twenty-four Wistar rats were randomized into six groups of four animals per group. The animals in Group 1 were administered placebo and designated as control, while the rats in Groups 2 to 6 were administered 1000, 1500, 2000, 2500, and 3000 mg/kg bodyweight single oral dose of KWAPF01, respectively, and subsequently monitored for gross morphological and behavioural changes for 72 h. Piloerection, reduced motility, and tremor were observed in experimental groups, and the median lethal dose (LD(50)) of the extract was 2225.94 mg/kg bodyweight. The 11 compounds identified through HPLC analysis of the extract were docked against acetylcholinesterase (AChE), and the docking scores ranged from −5.3 to −10.8 kcal/mol, with catechol (−5.3 kcal/mol) and berberine (−10.8 kcal/mol) having the highest and lowest binding energies, respectively. Judging by the results, it could be inferred that some of the constituents of KWAPF01 have a direct impact on the nervous system and this is possibly elicited via the cholinergic system as it contains a nicotinic acetylcholine receptors agonist and potential inhibitors of AChE. Therefore, the use of KWAPF01 needs to be cautiously guided.
format Online
Article
Text
id pubmed-9307333
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-93073332022-07-23 Toxicological Evaluation and In Silico Identification of Acetylcholinesterase Inhibitors in a Commercial Polyherbal Formulation (KWAPF01) Aladodo, A. Raliat Ibrahim, Ibrahim O. Sabiu, Saheed Evid Based Complement Alternat Med Research Article This study investigated the toxicological implications of a commercial polyherbal formulation, KWAPF01. Twenty-four Wistar rats were randomized into six groups of four animals per group. The animals in Group 1 were administered placebo and designated as control, while the rats in Groups 2 to 6 were administered 1000, 1500, 2000, 2500, and 3000 mg/kg bodyweight single oral dose of KWAPF01, respectively, and subsequently monitored for gross morphological and behavioural changes for 72 h. Piloerection, reduced motility, and tremor were observed in experimental groups, and the median lethal dose (LD(50)) of the extract was 2225.94 mg/kg bodyweight. The 11 compounds identified through HPLC analysis of the extract were docked against acetylcholinesterase (AChE), and the docking scores ranged from −5.3 to −10.8 kcal/mol, with catechol (−5.3 kcal/mol) and berberine (−10.8 kcal/mol) having the highest and lowest binding energies, respectively. Judging by the results, it could be inferred that some of the constituents of KWAPF01 have a direct impact on the nervous system and this is possibly elicited via the cholinergic system as it contains a nicotinic acetylcholine receptors agonist and potential inhibitors of AChE. Therefore, the use of KWAPF01 needs to be cautiously guided. Hindawi 2022-07-15 /pmc/articles/PMC9307333/ /pubmed/35873645 http://dx.doi.org/10.1155/2022/4388941 Text en Copyright © 2022 A. Raliat Aladodo et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Aladodo, A. Raliat
Ibrahim, Ibrahim O.
Sabiu, Saheed
Toxicological Evaluation and In Silico Identification of Acetylcholinesterase Inhibitors in a Commercial Polyherbal Formulation (KWAPF01)
title Toxicological Evaluation and In Silico Identification of Acetylcholinesterase Inhibitors in a Commercial Polyherbal Formulation (KWAPF01)
title_full Toxicological Evaluation and In Silico Identification of Acetylcholinesterase Inhibitors in a Commercial Polyherbal Formulation (KWAPF01)
title_fullStr Toxicological Evaluation and In Silico Identification of Acetylcholinesterase Inhibitors in a Commercial Polyherbal Formulation (KWAPF01)
title_full_unstemmed Toxicological Evaluation and In Silico Identification of Acetylcholinesterase Inhibitors in a Commercial Polyherbal Formulation (KWAPF01)
title_short Toxicological Evaluation and In Silico Identification of Acetylcholinesterase Inhibitors in a Commercial Polyherbal Formulation (KWAPF01)
title_sort toxicological evaluation and in silico identification of acetylcholinesterase inhibitors in a commercial polyherbal formulation (kwapf01)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307333/
https://www.ncbi.nlm.nih.gov/pubmed/35873645
http://dx.doi.org/10.1155/2022/4388941
work_keys_str_mv AT aladodoaraliat toxicologicalevaluationandinsilicoidentificationofacetylcholinesteraseinhibitorsinacommercialpolyherbalformulationkwapf01
AT ibrahimibrahimo toxicologicalevaluationandinsilicoidentificationofacetylcholinesteraseinhibitorsinacommercialpolyherbalformulationkwapf01
AT sabiusaheed toxicologicalevaluationandinsilicoidentificationofacetylcholinesteraseinhibitorsinacommercialpolyherbalformulationkwapf01